Article Directory

Amgen NASDAQ: AMGN pharmaceutical company just announced positive performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.

Study reached primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the premier fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an essential regulator of osteoclasts the cells that break down bone). Denosumab is being investigated for its potential to inhibit every stage of osteoclast activity by a targeted mechanism. Denosumab is being studied for a variety of bone loss conditions including postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to delay bone metastases and stop and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a global problem illness that is increasing in dominance as the population of the world both increases and ages. The World Health Organization (WHO) has recently identified osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this horrendous disease.

Amgen states that the economic burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Clinical pharmacist have been developing prescriptions drugs to help patient that have serious side effects. These products are created simultaneously the medications that aid in the treatment of the primary illness. The fact that data is available to help anticipate the possible effects and interactions drugs have with each other is outstanding.

These medicines are used to both prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth may reduce the danger of broken bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.